NeuroPace Secures $75 Million Credit Facility with MidCap

NeuroPace ( (NPCE) ) just unveiled an announcement.

On June 4, 2025, NeuroPace, Inc. entered into a $75 million credit facility with MidCap Financial, comprising a $60 million term loan and a $15 million revolving credit facility. This new financing arrangement allowed NeuroPace to repay its existing loan with CRG Partners IV, L.P., and the revolving credit will support working capital and corporate purposes. The favorable terms of the new credit facility are expected to reduce cash interest expenses and support NeuroPace’s growth initiatives, including expanding access to the RNS System and investing in new product developments.

The most recent analyst rating on (NPCE) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on NeuroPace stock, see the NPCE Stock Forecast page.

Spark’s Take on NPCE Stock

According to Spark, TipRanks’ AI Analyst, NPCE is a Neutral.

The overall score reflects the challenges in financial performance with profitability and liquidity issues, offset by positive earnings call guidance and corporate events. Technical analysis and valuation provide moderate support.

To see Spark’s full report on NPCE stock, click here.

More about NeuroPace

NeuroPace, Inc., based in Mountain View, California, is a medical device company dedicated to improving the lives of individuals with epilepsy. It offers the RNS System, a unique brain-responsive platform that provides personalized, real-time treatment for seizures, aiming to enhance the standard of care for patients with drug-resistant epilepsy and potentially other brain disorders.

Average Trading Volume: 286,447

Technical Sentiment Signal: Buy

Current Market Cap: $427.7M

Find detailed analytics on NPCE stock on TipRanks’ Stock Analysis page.